^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PRDM1 (PR/SET Domain 1)

    i
    Other names: PRDM1, PR/SET Domain 1, PRDI-BF1, PR Domain Containing 1, With ZNF Domain, PR Domain Zinc Finger Protein 1, PR Domain 1, BLIMP1, Beta-Interferon Gene Positive-Regulatory Domain I Binding Factor, Beta-Interferon Gene Positive Regulatory Domain I-Binding Factor, Positive Regulatory Domain I-Binding Factor 1, B-Lymphocyte-Induced Maturation Protein 1, PR Domain-Containing Protein 1, PRDI-Binding Factor-1
    21h
    PRDM1 restricts bladder cancer progression and enhances chemosensitivity by suppressing OTUD6A-mediated deubiquitination of CDC6. (PubMed, Cell Death Dis)
    Collectively, these findings demonstrate that PRDM1 acts as a tumor suppressor in BCa by inhibiting OTUD6A transcription and promoting CDC6 degradation. We propose a PRDM1‒OTUD6A‒CDC6 axis model, providing novel insights into PRDM1 as a potential therapeutic target in BCa.
    Journal
    |
    PRDM1 (PR/SET Domain 1) • CDC6 (Cell Division Cycle 6)
    8d
    PRDM1 Knockdown Promotes Ferroptosis and Sunitinib Sensitivity by Modulating the PI3K/Akt Signaling Through Inhibition of ESM1 Transcription in Renal Cell Carcinoma. (PubMed, Kaohsiung J Med Sci)
    Taken together, our study shows that PRDM1 silencing promotes ferroptosis and sunitinib sensitivity by inhibiting ESM1 transcription and modulating PI3K/Akt signaling in RCC. Our findings thus provide novel insights for therapeutically targeting RCC.
    Journal
    |
    PRDM1 (PR/SET Domain 1) • ESM1 (Endothelial Cell Specific Molecule 1)
    |
    sunitinib
    19d
    Gene Regulatory Programs of NK Cells Show That NCAM1 (CD56) and KIRs Are Controlled by Genetically Polymorphic Distal Regulatory Elements. (PubMed, Eur J Immunol)
    We identify an NCAM1 DRE that binds STAT3 in most NK cells, while identifying a genetic cohort that has motifs for binding repressive BLIMP1 at the DRE and resulting in less CD56 expression. Together, our findings reveal novel epigenetic and transcriptomic systems for the regulation of NK cell receptors driving NK cell cytotoxicity and diversity.
    Journal • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • NCAM1 (Neural cell adhesion molecule 1) • PRDM1 (PR/SET Domain 1) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2) • NKG2D (killer cell lectin like receptor K1)
    27d
    Natural Product Driven Activation of UCP1 and Tumor Metabolic Suppression: Integrating Thermogenic Nutrient Competition with Cancer Metabolic Reprogramming. (PubMed, Biomolecules)
    Importantly, many of these compounds also inhibit cancer cell intrinsic metabolism by reducing glycolysis, oxidative phosphorylation, lipid synthesis, and amino acid dependent anaplerosis. This review integrates UCP1 biology, natural product mediated thermogenesis, molecular docking evidence, and tumor metabolic suppression, proposing a unified framework in which natural compounds impose coordinated metabolic pressure on cancer through both adipocyte-driven nutrient competition and direct inhibition of tumor metabolism.
    Review • Journal
    |
    PRDM1 (PR/SET Domain 1) • SIRT1 (Sirtuin 1) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • PPARGC1A (PPARG Coactivator 1 Alpha) • PRDM16 (PR/SET Domain 16)
    1m
    Distinct Molecular and Prognostic Profiles of Left- and Right-Sided Colorectal Cancer Revealed by NGS Analysis: The Role of SMAD4 and SETD2 Mutations. (PubMed, Cancer Med)
    These findings reveal criticalmolecular and prognostic differences between LCC and RCC and highlight SMAD4 and SETD2 asimportant prognostic biomarkers, suggesting the potential value of location-and mutation-guided precision therapies in CRC.
    Retrospective data • Journal • Next-generation sequencing
    |
    BRAF (B-raf proto-oncogene) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • PRDM1 (PR/SET Domain 1) • PI3K (Phosphoinositide 3-kinases)
    |
    BRAF mutation • ARID1A mutation
    1m
    Pan-cancer epigenetic landscape of human tumor-associated macrophages reveals crucial enhancers governing their heterogenous formation by Pol II pausing modulation. (PubMed, J Adv Res)
    Our work delineates the epigenetic and transcriptional circuitry that establishes TAM heterogeneity as potential therapeutic levers to enhance cancer immunotherapy.
    Journal • IO biomarker • Pan tumor
    |
    SPP1 (Secreted Phosphoprotein 1) • HES1 (Hes Family BHLH Transcription Factor 1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PRDM1 (PR/SET Domain 1)
    1m
    PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma. (PubMed, Adv Sci (Weinh))
    Our findings identify PRDM1 as a key factor associated with nICRT resistance and suggest that targeting ferroptosis pathways or disrupting PRDM1+ cell-mediated immune suppression may represent a viable strategy in ESCC. Clinical trial registration number: NCT03940001.
    Journal
    |
    IL1A (Interleukin 1, alpha) • PRDM1 (PR/SET Domain 1) • SIRPA (Signal Regulatory Protein Alpha)
    2ms
    PRDM1-driven SLC30A9 overexpression contributes to the malignant phenotype of cervical cancer cells via promoting mitochondrial hyperfunction. (PubMed, Cell Death Dis)
    These SLC30A9-silenced xenografts exhibited mitochondrial dysfunction, proliferation inhibition and apoptosis induction. These findings collectively suggest that PRDM1-driven SLC30A9 overexpression significantly contributes to the malignant phenotype of cervical cancer, possibly through promoting mitochondrial hyperfunction.
    Journal
    |
    PRDM1 (PR/SET Domain 1)
    2ms
    RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma. (PubMed, Cancer Biol Ther)
    Although lenalidomide/bortezomib/dexamethasone (RVd) and cyclophosphamide/bortezomib/dexamethasone (CyBorD) are clinically effective, their precise impacts on PC/B-cell maturation remain unclear. RVd responders further downregulated CD56, CD269, and CD329, and increased CD243. These shared and divergent modulations elucidate the molecular underpinnings of RVd and CyBorD efficacy and inform precision regimen selection.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • TNFRSF17 (TNF Receptor Superfamily Member 17) • RARA (Retinoic Acid Receptor Alpha) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • PAX5 (Paired Box 5) • KLF4 (Kruppel-like factor 4) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD200 (CD200 Molecule) • IRF4 (Interferon regulatory factor 4) • CD52 (CD52 Molecule) • PRDM1 (PR/SET Domain 1) • NANOG (Nanog Homeobox) • NES (Nestin) • XBP1 (X-box-binding protein 1) • CD81 (CD81 Molecule) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • SLAMF7 (SLAM Family Member 7) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    |
    lenalidomide • bortezomib • cyclophosphamide
    3ms
    Key regulatory roles of PRDM1 in human NK-cell differentiation and activation. (PubMed, Leukemia)
    As a homeostatic factor, PRDM1 is induced upon IL-2 and feeder cell stimulation, but its ability to restrict NK-cell growth upon feeder stimulation may be counteracted by the AP-1-induced transcriptional network. The loss of PRDM1 activity is frequent in NK-cell malignancies which may lead to decreased homeostatic control, impaired terminal differentiation, enhanced cellular fitness, and the acquisition of more stem-like features, thereby promoting lymphomagenesis.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL2 (Interleukin 2) • PRDM1 (PR/SET Domain 1) • NKG2D (killer cell lectin like receptor K1)
    3ms
    Discovery and Characterization of Novel BLIMP-1 Heterobifunctional Ligand-Directed Degraders. (PubMed, J Med Chem)
    It is predicted that perturbation of BLIMP-1 will significantly impact tumor cell homeostasis and ultimately reduce MM cell survival. Herein, we describe the discovery and optimization of the first orally bioavailable BLIMP-1 heterobifunctional ligand-directed degrader (LDD) and demonstration of the expected antitumor response and immunomodulatory biology following BLIMP-1 degradation using preclinical in vivo MM models.
    Journal
    |
    PRDM1 (PR/SET Domain 1)
    3ms
    Obesity Impairs the Antitumor Activity of CAR-T Cells in Triple-Negative Breast Cancer. (PubMed, bioRxiv)
    This study highlights obesity as an understudied and critically important covariate for adoptive T-cell therapy and demonstrates important links between systemic metabolism and antigen expression. This work paves the way for future mechanistic and translational research into how obesity impacts CAR-T cell functionality.
    Journal • IO biomarker
    |
    PRDM1 (PR/SET Domain 1)